Screener
AnaptysBio, Inc. ANAB Q2 2026 earnings
Reported September 21, 2026 · After market close
Revenue$27.5MBeat by $13.4M
EPS$5.11Beat by $5.58
Revenue estimate$14.1M
EPS estimate-$0.47
“Jemperli continues to demonstrate robust year-over-year growth with major catalysts within the next 6 months including further sales acceleration ex-US, anticipated FDA approval of Jemperli in monotherapy in dMMR/MSI-H neoadjuvant rectal cancer, as well as a judgement expected in our litigation with GSK and Tesaro. In addition to Jemperli, we anticipate FDA approval of Quimilza in GPP in December 2026.”
Next report
Nov 3, 2026 (In 3 weeks)Revenue estimate$25.6M
EPS estimate-$1.84
Valuation & ratios
Valuation
as of 10/09/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did AnaptysBio, Inc. report Q2 2026 earnings?
- AnaptysBio, Inc. (ANAB) reported Q2 2026 earnings on September 21, 2026 after market close.
- What were AnaptysBio, Inc.'s Q2 2026 revenue and EPS?
- AnaptysBio, Inc. reported revenue of $27.5M and eps of $5.11 for Q2 2026.
- Did AnaptysBio, Inc. beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $14.1M by $13.4M. EPS beat the consensus estimate of $-0.47 by $5.58.
- How did AnaptysBio, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 23.5% from $22.3M a year earlier.
- Where can I find AnaptysBio, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-396690) directly on SEC EDGAR. The filing index links above go to sec.gov.
